Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization

References

• D’Agostino RB, R.ussell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am. Heart J.139(2 Pt 1), 272–281 (2000).
   PubMed Web of Science ®Google Scholar
• Greenland P, Knoll MD, Stamler J et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA290(7), 891–897 (2003).
   PubMed Web of Science ®Google Scholar
• Ni H, Coady S, Rosamond W et al. Trends from 1987 to 2004 in sudden death due to coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J.157(1), 46–52 (2009).
   PubMedGoogle Scholar
• Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol.102(10 Suppl.), 1K–34K (2008).
   Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med.62(5), 707–714 (1977).
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis124, S11–S20 (1996).
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol.21(4), 312–318 (2010).
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther.111(3), 893–908 (2006).
   PubMed Web of Science ®Google Scholar
• Heinecke JW. The HDL proteome: a marker – and perhaps mediator – of coronary artery disease. J. Lipid Res.50, S167–S171 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J.31(2), 149–164 (2010).
   PubMed Web of Science ®Google Scholar
• Brundert M, Heeren J, Merkel M et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins by tissues in mice and by cultured cells. J. Lipid Res. DOI: 10.1194/jlr.M011981 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Fabre AC, Malaval C, Ben Addi A et al. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology52, 1477–1483 (2010).
   PubMedGoogle Scholar
• Webb NR, Cai L, Ziemba KS et al. The fate of HDL particles in vivo after SR-BI–mediated selective lipid uptake. J. Lipid Res.43, 1890–1898 (2002).
   PubMed Web of Science ®Google Scholar
• Webb NR, De Beer MC, Asztalos BF et al. Remodeling of HDL remnants generated by scavenger receptor class B type I. J. Lipid Res.45, 1666–1673 (2004).
   PubMedGoogle Scholar
• Kozyraki R, Fyfe J, Kristiansen M et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat. Med.5, 656–661 (1999).
   PubMed Web of Science ®Google Scholar
• Lee JY, Lanningham-Foster L, Boudyguina EY et al. Pre-β high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J. Lipid Res.45, 716–728 (2004).
   PubMedGoogle Scholar
• Ghosh S, Zhao B, Bie J, Song J. Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul. Pharmacol.52(1–2), 1–10 (2010).
   PubMedGoogle Scholar
• Jian B, de la Llera-Moya M, Royer L et al. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J. Lipid Res.38, 734–744 (1997).
   PubMed Web of Science ®Google Scholar
• Adorni MP, Zimetti F, Billheimer JT et al. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res.48(11), 2453–2462 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao B, Song J, St Clair RW, Ghosh S. Stable over-expression of human macrophage cholesteryl ester hydrolase (ceh) results in enhanced free cholesterol efflux from human thp1-macrophages. Am. J. Physiol. Cell Physiol.292(1), C405–C412 (2007).
   Google Scholar
• Zhou H, Tan KC, Shiu SW, Wong Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab. Res. Rev.24(8), 617–623 (2008).
   PubMedGoogle Scholar
• Zhou H, Shiu SW, Wong Y, Tan KC. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in Type 2 diabetes mellitus. Diab. Vasc. Dis. Res.6(4), 238–243 (2009).
   PubMedGoogle Scholar
• Ripollés Piquer B, Nazih H, Bourreille A et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism55(7), 980–988 (2006).
   PubMed Web of Science ®Google Scholar
• Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr. Opin. Lipidol.13(5), 483–488 (2002).
   PubMed Web of Science ®Google Scholar
• Kruth HS, Jones NL, Huang W et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem.1280(3), 2352–2360 (2005).
   Google Scholar
• Kruth HS, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem.277(37), 34573–34580 (2002).
   PubMed Web of Science ®Google Scholar
• Choi SH, Harkewicz R, Lee JH et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ. Res.104, 1355–1363 (2009).
   PubMed Web of Science ®Google Scholar
• Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim. Biophys. Acta,1529(1–3), 164–174 (2000).
   PubMed Web of Science ®Google Scholar
• Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J. Biol. Chem.255(19), 9344–9352 (1980).
   PubMed Web of Science ®Google Scholar
• Rothblat GH, de la Llera-Moya M, Favari E, Yancey PG, Kellner-Weibel G. Cellular cholesterol flux studies: methodological considerations. Atherosclerosis163(1), 1–8 (2002).
   PubMedGoogle Scholar
• Ishii I, Oka M, Katto N, Shirai K, Saito Y, Hirose S. β-VLDL-induced cholesterol ester deposition in macrophages may be regulated by neutral cholesterol esterase activity. Arterioscler. Thromb.12, 1139–1145 (1992).
   PubMedGoogle Scholar
• Mathur SN, Field FJ, Megan MB, and Armstrong HL. A defect in mobilization of cholesteryl esters in rabbit macrophages. Biochim. Biophys. Acta834, 48–57 (1985).
   PubMedGoogle Scholar
• Yancey PG and St. Clair RW. Mechanism of the defect in cholesteryl ester clearance from macrophages of atherosclerosis-susceptible White Carneau pigeons. J. Lipid Res.35, 2114–2129 (1994).
   PubMed Web of Science ®Google Scholar
• Brunham LR, Singaraja RR, Duong M et al. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler. Thromb. Vasc. Biol.29(4), 548–554 (2009).
   PubMed Web of Science ®Google Scholar
• Burgess B, Naus K, Chan J et al. Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.28(10), 1731–1737 (2008).
   PubMedGoogle Scholar
• Yvan-Charvet L, Ranalletta M, Wang N et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest.117(12), 3900–3908 (2007).
   PubMed Web of Science ®Google Scholar
• Singaraja RR, Fievet C, Castro G et al. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest.110, 35–42 (2002).
   PubMed Web of Science ®Google Scholar
• Joyce CW, Wagner EM, Basso F et al. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J. Biol. Chem.281(44), 33053–33065 (2006).
   PubMedGoogle Scholar
• Ye D, Lammers B, Zhao Y et al. ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr. Drug. Targets PubMed PMID: 21039336 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci.12, 194–199 (1991).
   PubMed Web of Science ®Google Scholar
• Matsuda K. ACAT inhibitors as antiatherosclerotic agents. Med. Res. Rev.14, 271–305 (1994).
   PubMed Web of Science ®Google Scholar
• Matsuo M , Ito F, Konto A, Aketa M, Tomoi M, Shimomura K. Effect of FR145237, a novel ACAT inhibitor on atherogenesis in cholesterol fed and WHHl rabbits. Evidence for a direct effect on the arterial wall. Biochem. Biophys. Acta1259, 254–260 (1995).
   PubMedGoogle Scholar
• Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI 1011 is effective in the prevention and regression of aortic fatty streak in hamsters. Atherosclerosis137, 77–85 (1998).
   PubMed Web of Science ®Google Scholar
• Perrey S, Legendre C, Matsuura A et al. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis155, 359–370 (2001).
   PubMedGoogle Scholar
• Accad M, Smith S, Newland D et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase-1. J. Clin. Invest.105, 711–719 (2000).
   PubMed Web of Science ®Google Scholar
• Yagu H, Kitamine T, Osuga J et al. Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J. Biol. Chem.275, 21324–21330 (2000).
   PubMedGoogle Scholar
• Fazio S, Major AS, Swift LL et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J. Clin. Invest.107, 163–171 (2001).
   PubMedGoogle Scholar
• Bocan TM, Krause BR, Rosebury WS et al. The ACAT inhibitor avasimbe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesion of hypercholesterolemic rabbits. Arteioscler. Thromb. Vasc. Biol.20, 70–79 (2000).
   PubMed Web of Science ®Google Scholar
• Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell104, 503–516 (2001).
   PubMed Web of Science ®Google Scholar
• Warner GJ, Stoudt G, Bamberger M, Johnson WJ, Rothblat GH. Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J. Biol. Chem.270, 5772–5778 (1995).
   PubMed Web of Science ®Google Scholar
• Ghosh S, St Clair RW, Rudel LL. Mobilization of cytoplasmic CE droplets by over-expression of human macrophage cholesteryl ester hydrolase. J. Lipid Res.44, 1833–1840 (2003).
   PubMedGoogle Scholar
• Ghosh S. Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing and expression of full-length cDNA. Physiol. Genomics2, 1–8 (2000).
   PubMedGoogle Scholar
• Zhao B, Fisher BJ, St Clair RW, Rude LL, Ghosh S. Redistribution of macrophage cholesteryl ester hydrolase from cytoplasm to lipid droplets upon lipid loading. J. Lipid Res.46, 2114–2121 (2005).
   PubMedGoogle Scholar
• Crow JA, Middleton BL, Borazjani A, Hatfield MJ, Potter PM, Ross MK. Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte/macrophages. Biochim. Biophys. Acta1781(10), 643–654 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao B, Song J, Chow WN, St Clair RW, Rudel LL, Ghosh S. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J. Clin. Invest.117(10), 2983–2992 (2007).
   PubMedGoogle Scholar
• Zhao B, Song J, Ghosh S. Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. J. Lipid Res.49(10), 2212–2217 (2008).
   PubMedGoogle Scholar
• Fazio S, Linton MF. The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall. Am. J. Cardiol.88, 12E–15E (2001).
   Google Scholar
• Koseki M, Hirano K, Masuda D et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-α secretion in Abca1-deficient macrophages. J. Lipid Res.48, 299–306 (2007).
   PubMedGoogle Scholar
• Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl Acad. Sci. USA90, 12040–12044 (1993).
   PubMed Web of Science ®Google Scholar
• Francone OL, Royer L, Boucher G et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler. Thromb. Vasc. Biol.25, 1198–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol.30(2), 139–143 (2010).
   PubMed Web of Science ®Google Scholar
• Patel S, Drew BG, Nakhla S et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with Type 2 diabetes. J. Am. Coll. Cardiol.53, 962–971 (2009).
   PubMed Web of Science ®Google Scholar
• Bie J, Zhao B, Song J, Ghosh S. Improved insulin sensitivity in high fat- and high cholesterol-fed Ldlr-/- mice with macrophage-specific transgenic expression of cholesteryl ester hydrolase: role of macrophage inflammation and infiltration into adipose tissue. J. Biol. Chem.285(18), 13630–13637 (2010).
   PubMed Web of Science ®Google Scholar
• Besedovsky HO, Del Rey A. Metabolic and endocrine actions of interleukin-1. Effects on insulin-resistant animals. Ann. NY Acad. Sci.594, 214–221 (1990).
   PubMed Web of Science ®Google Scholar
• Vozarova B, Weyer C, Hanson K, Tataranni P, Bogardus C, Pratley R. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res.9, 414–417 (2001).
   PubMedGoogle Scholar
• Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science259, 87–91 (1993).
   PubMed Web of Science ®Google Scholar
• Taishi P, Churchill L, De A, Obal F, Krueger JM. Cytokine mRNA induction by interleukin-1β or tumor necrosis factor alpha in vitro and in vivo. Brain Res.1226, 89–98 (2008).
   PubMedGoogle Scholar
• Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun.311, 372–379 (2003).
   PubMed Web of Science ®Google Scholar
• Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology148, 241–251, (2007).
   PubMed Web of Science ®Google Scholar
• Alvarez B, Quinn LS, Busquets B, Quiles MT, Lopez-Soriano FJ, Argiles JM. Tumor necrosis factor-α exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochim. Biophys. Acta1542, 66–72 (2002).
   PubMedGoogle Scholar
• Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-1β targeted therapy for Type 2 diabetes. Expert Opin. Biol. Ther.9, 1177–1188 (2009).
   PubMed Web of Science ®Google Scholar
• Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis.47, 139–148 (2006).
   PubMed Web of Science ®Google Scholar
• Soriano S, Gonzalez L, Martin-Malo A et al. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3–5 patients. Clin. Nephrol.67, 352–357 (2007).
   PubMed Web of Science ®Google Scholar
• Shah DS, Polkinhorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton)13, 667–671 (2008).
   PubMedGoogle Scholar
• Parekh RS, Plantinga LC, Kao WH et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int.74, 1335–1342 (2008).
   PubMedGoogle Scholar
• Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr. Opin. Nephrol. Hypertens.18(3), 181–188 (2009).
   PubMed Web of Science ®Google Scholar
• Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl. Res.153(2), 77–85 (2009).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA290(17), 2292–2300 (2003).
   PubMed Web of Science ®Google Scholar
• Vakili L, Hama S, Kim JB et al. The effect of HDL mimetic peptide 4F on PON1. Adv. Exp. Med. Biol.660, 167–172 (2010).
   PubMedGoogle Scholar
• Smith JD. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs11(9), 989–996 (2010).
   PubMedGoogle Scholar
• Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol. Rev.18(3), 141–147 (2010).
   PubMed Web of Science ®Google Scholar
• White CR, Datta G, Mochon P et al. Vasculoprotective effects of apolipoprotein mimetic peptides: an evolving paradigm in HDL therapy. Vasc. Dis. Prev.6, 122–130 (2009).
   PubMedGoogle Scholar
• Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med.3(10), 540–547 (2006).
   PubMedGoogle Scholar